Management of COVID-19 in cancer patients receiving cardiotoxic anti-cancer therapy. Future recommendations for cardio-oncology
Cardiotoxicity induced by anti-cancer treatment has become a significant threat as the number of cardiotoxic anti-cancer agents is growing. Cancer patients are at an increased risk of contracting coronavirus disease 2019 (COVID-19) because of immune suppression caused by anti-cancer drugs and/or sup...
Saved in:
Main Authors: | Hasan Kobat (Author), Islam Elkonaissi (Author), Mehmet Tevfik Dorak (Author), Shereen Nabhani-Gebara (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2021-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Editorial: Impact of COVID-19 on cancer care and rehabilitation
by: Melanie Dalby, et al.
Published: (2023) -
Pediatric Cardio-Oncology: Screening, Risk Stratification, and Prevention of Cardiotoxicity Associated with Anthracyclines
by: Xiaomeng Liu, et al.
Published: (2024) -
Comparison of Patients' Phenotypes, Guideline-Directed Recommendations Compliance and Rates of Cardiotoxicity between Caribbean and United States Cardio-oncology Programs
by: Pamela Piña, et al.
Published: (2022) -
Cancer Immunoprevention and Public Health
by: Sandeep K. Singh, et al.
Published: (2017) -
Cancer literacy among Jordanian colorectal cancer survivors and informal carers: Qualitative explorations
by: Samar J. Melhem, et al.
Published: (2023)